{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:08:36Z","timestamp":1768486116748,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The MIC, determined in vitro using a fixed tazobactam concentration, is used as basis for the pharmacokinetic\/pharmacodynamic (PK\/PD) index of piperacillin\/tazobactam. The \u03b2-lactamase inhibitor (BLI) concentration-dependent MIC (MICcBLI) represents a promising alternative PD metric accounting for varying tazobactam concentrations observed in vivo. The aim was to investigate how the effect of varying in vivo tazobactam concentrations can be incorporated through the in vitro MICcBLI as a PD metric to assess the probability of three piperacillin\/tazobactam dosing regimens to achieve predefined target values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MICcBLI for six isolates was evaluated as function of tazobactam concentrations. Two nonlinear mixed-effects PK models for piperacillin and tazobactam were developed based on data from 44 critically ill patients. Probability of target attainment (PTA) analysis was performed, and PTA values for the PK\/PD targets 100% fT\u200a&amp;gt;\u200aMIC and 100% fT\u200a&amp;gt;\u200aMICcBLI were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The susceptibility against piperacillin was dependent on the tazobactam concentration for all isolates. A two-compartment PK model with inter-occasion variability on clearance (CL) and inter-individual variability on CL and both volumes, with creatinine clearance as a covariate on CL, described the PK of piperacillin and tazobactam best. The PTA analysis revealed differences between the isolates, three infusion types and the two metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By adopting this framework, dosing optimization can be approached to provide support for the rational design of piperacillin\/tazobactam dosing regimens and other \u03b2-lactam\/\u03b2-lactamase combinations. The shift from the conventional MIC to a \u03b2-lactamase inhibitor concentration-dependent metric clearly improved the knowledge of the susceptibility of a pathogen against piperacillin\/tazobactam.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf406","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:04:36Z","timestamp":1763028276000},"source":"Crossref","is-referenced-by-count":0,"title":["The \u03b2-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic\/pharmacodynamic relationship of piperacillin\/tazobactam for dosing optimization"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2418-9500","authenticated-orcid":false,"given":"Malin","family":"Andersson","sequence":"first","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4654-7434","authenticated-orcid":false,"given":"Franz","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-3890","authenticated-orcid":false,"given":"Ferdinand","family":"Weinelt","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3157-814X","authenticated-orcid":false,"given":"Nicole","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jette","family":"Jung","sequence":"additional","affiliation":[{"name":"Max von Pettenkofer Institute, Faculty of Medicine, Ludwig-Maximilians-Universit\u00e4t , Pettenkoferstra\u00dfe 9a, 80366 Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zoller","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Hospital of the Ludwig-Maximilians-University of Munich , Marchioninistrasse 15, 81377 Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Zander","sequence":"additional","affiliation":[{"name":"Laboratory of Dr. Brunner , Luisenstr. 7e, 78464 Konstanz ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-3914","authenticated-orcid":false,"given":"Wilhelm","family":"Huisinga","sequence":"additional","affiliation":[{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Institute of Mathematics, Universit\u00e4t Potsdam , Karl-Liebknecht-Str. 24\/25, Potsdam, 14476 Golm ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9344-8514","authenticated-orcid":false,"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]},{"name":"Graduate Research Training Program PharMetrX, Institute of Pharmacy, Freie Universit\u00e4t Berlin , Kelchstr. 31, 12169 Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2026011413270964300_dkaf406-B1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00134-017-5036-1","article-title":"Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM\/ESCMID\/WAAAR round table on multi-drug resistance","volume":"44","author":"De Waele","year":"2018","journal-title":"Intensive Care Med"},{"key":"2026011413270964300_dkaf406-B2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"2019 diseases and injuries collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"GBD","year":"2022","journal-title":"Lancet"},{"key":"2026011413270964300_dkaf406-B3","doi-asserted-by":"crossref","unstructured":"Hayashi Y, Roberts JA, Paterson DL \u00a0et al \u00a0Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol \u00a02010; 6: 1017\u201331. 10.1517\/17425255.2010.506187","DOI":"10.1517\/17425255.2010.506187"},{"key":"2026011413270964300_dkaf406-B4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011413270964300_dkaf406-B5","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2026011413270964300_dkaf406-B6","author":"EUCAST"},{"key":"2026011413270964300_dkaf406-B7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/INF.0b013e3182a743c7","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in critically ill young children","volume":"33","author":"Cies","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2026011413270964300_dkaf406-B9","doi-asserted-by":"publisher","first-page":"e1585","DOI":"10.1002\/cnr2.1585","article-title":"Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever","volume":"5","author":"Maarbjerg","year":"2022","journal-title":"Cancer Rep"},{"key":"2026011413270964300_dkaf406-B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijid.2020.01.010","article-title":"Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy","volume":"92","author":"Bue","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2026011413270964300_dkaf406-B11","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1128\/AAC.06113-11","article-title":"Novel modeling framework to guide design of optimal dosing strategies for \u03b2-lactamase inhibitors","volume":"56","author":"Bhagunde","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413270964300_dkaf406-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01906-18","article-title":"Optimal piperacillin-tazobactam dosing strategies against extended-spectrum-lactamase-producing Enterobacteriaceae","volume":"63","author":"Abodakpi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413270964300_dkaf406-B13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jac\/dkae443","article-title":"Simulated achievement rate of \u03b2-lactams\/nacubactam treatment in humans using instantaneous MIC-based PK\/PD analysis","volume":"80","author":"Igarashi","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-758-7_1","article-title":"Enzyme kinetics in drug metabolism: fundamentals and applications","volume":"1113","author":"Nagar","year":"2014","journal-title":"Methods Mol Biol"},{"key":"2026011413270964300_dkaf406-B15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"key":"2026011413270964300_dkaf406-B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9485-1","volume-title":"Pharmacokinetic-Pharmacodynamic Modeling and Simulation","author":"Bonate","year":"2011"},{"key":"2026011413270964300_dkaf406-B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13054-016-1255-z","article-title":"Piperacillin concentration in relation to therapeutic range in critically ill patients\u2014a prospective observational study","volume":"20","author":"Zander","year":"2016","journal-title":"Crit Care"},{"key":"2026011413270964300_dkaf406-B18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"2026011413270964300_dkaf406-B19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"2026011413270964300_dkaf406-B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/antibiotics9030131","article-title":"Therapeutic drug monitoring of meropenem and piperacillin in critical illness\u2014experience and recommendations from one year in routine clinical practice","volume":"9","author":"Scharf","year":"2020","journal-title":"Antibiotics"},{"key":"2026011413270964300_dkaf406-B21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"2026011413270964300_dkaf406-B22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/FTD.0000000000000602","article-title":"Measuring unbound versus total piperacillin concentrations in plasma of critically ill patients: methodological issues and relevance","volume":"41","author":"Colman","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2026011413270964300_dkaf406-B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","article-title":"The chemistry, pharmacokinetics and tissue distribution of piperatillin\/tazobactam","volume":"31","author":"S\u00f6rgel","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B24","author":"FDA"},{"key":"2026011413270964300_dkaf406-B25","author":"EMA"},{"key":"2026011413270964300_dkaf406-B26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijantimicag.2016.06.013","article-title":"Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients","volume":"48","author":"Zander","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413270964300_dkaf406-B27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10928-019-09633-8","article-title":"Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis","volume":"46","author":"Sukarnjanaset","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026011413270964300_dkaf406-B28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","article-title":"First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis","volume":"35","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413270964300_dkaf406-B29","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1128\/AAC.01347-15","article-title":"Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?","volume":"59","author":"\u00d6brink-Hansen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413270964300_dkaf406-B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jac\/dki243","article-title":"Population pharmacokinetics and pharmacodynamics of piperacillin\/tazobactam in patients with complicated intra-abdominal infection","volume":"56","author":"Li","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B31","doi-asserted-by":"publisher","first-page":"e02306","DOI":"10.1128\/AAC.02306-17","article-title":"Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered?","volume":"62","author":"Andersen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413270964300_dkaf406-B32","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/pharmaceutics13091380","article-title":"Similar piperacillin\/tazobactam target attainment in obese versus nonobese patients despite differences in interstitial tissue fluid pharmacokinetics","volume":"13","author":"Busse","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026011413270964300_dkaf406-B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40262-024-01460-6","article-title":"A pooled pharmacokinetic analysis for piperacillin\/tazobactam across different patient populations: from premature infants to the elderly","volume":"64","author":"Kong","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026011413270964300_dkaf406-B34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2026011413270964300_dkaf406-B35","doi-asserted-by":"publisher","first-page":"dlae036","DOI":"10.1093\/jacamr\/dlae036","article-title":"Defining the pharmacokinetic\/pharmacodynamic index of piperacillin\/tazobactam within a hollow-fibre infection model to determine target attainment in intensive care patients","volume":"6","author":"Wenker","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026011413270964300_dkaf406-B36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/antibiotics10060615","article-title":"Novel pharmacokinetic\/pharmacodynamic parameters quantify the exposure\u2013effect relationship of levofloxacin against fluoroquinolone-resistant Escherichia coli","volume":"10","author":"Seeger","year":"2021","journal-title":"Antibiotics"},{"key":"2026011413270964300_dkaf406-B37","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/jac\/dkab146","article-title":"Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic\/pharmacodynamic modelling","volume":"76","author":"Seeger","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B38","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf374","article-title":"Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications","author":"Malin","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026011413270964300_dkaf406-B39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2049","article-title":"Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations","volume":"109","author":"Kluwe","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026011413270964300_dkaf406-B40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026011413270964300_dkaf406-B41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026011413270964300_dkaf406-B42","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.3390\/pharmaceutics13122128","article-title":"Development of a model-informed dosing tool to optimise initial antibiotic dosing\u2014a translational example for intensive care units","volume":"13","author":"Weinelt","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026011413270964300_dkaf406-B43","author":"Bennett"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf406\/65280134\/dkaf406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf406\/65280134\/dkaf406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:15Z","timestamp":1768415235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf406\/8322188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf406","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,13]]},"article-number":"dkaf406"}}